...
首页> 外文期刊>Scandinavian journal of gastroenterology. >An immunohistochemical study of bcl-2 and p53 protein expression in pancreatic carcinomas.
【24h】

An immunohistochemical study of bcl-2 and p53 protein expression in pancreatic carcinomas.

机译:胰腺癌中bcl-2和p53蛋白表达的免疫组织化学研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Only a few articles have examined the relationship between bcl-2 expression and clinical findings or bcl-2 expression and p53 expression in pancreatic carcinomas. METHODS: We investigated bcl-2 protein and p53 protein expression by means of immunohistochemical methods. RESULTS: The immunostaining for bcl-2 was positive in 16 (20%) of 81 cases of pancreatic carcinoma. There were no significant correlations between bcl-2 expression and the age, gender, region of sampling, or clinical stage of the patients. Bcl-2 protein was detected more frequently in histologically high-grade pancreatic carcinomas (grade III, 31%; grade II, 14%; grade I, 0%); however, there was no significant difference in prognosis between patients with and without bcl-2 protein expression. Immunostaining for the p53 protein was positive in 45 (56%) of 81 cases of pancreatic carcinoma. There was no significant correlation between bcl-2 protein expression and p53 protein expression. CONCLUSION: Bcl-2 was often detected in histologically high-grade pancreatic carcinomas, although there was no significant correlation between bcl-2 expression and the prognosis.
机译:背景:仅有几篇文章探讨了胰腺癌中bcl-2表达与临床表现或bcl-2表达与p53表达之间的关系。方法:我们通过免疫组织化学方法研究了bcl-2蛋白和p53蛋白的表达。结果:81例胰腺癌中16例(20%)bcl-2免疫染色阳性。 bcl-2表达与患者的年龄,性别,采样区域或临床分期之间无显着相关性。在组织学上高度胰腺癌中,Bcl-2蛋白的检出率更高(III级,31%; II级,14%; I级,0%);然而,有和没有bcl-2蛋白表达的患者的预后没有显着差异。在81例胰腺癌中,有45例(56%)的p53蛋白免疫染色阳性。 bcl-2蛋白表达与p53蛋白表达之间无显着相关性。结论:在组织学上高度分级的胰腺癌中经常检测到Bcl-2,尽管bcl-2表达与预后之间无显着相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号